An Integrated Model of Eicosanoid Metabolism and Signaling Based on Lipidomics Flux Analysis  by Gupta, Shakti et al.
4542 Biophysical Journal Volume 96 June 2009 4542–4551An Integrated Model of Eicosanoid Metabolism and Signaling Based on
Lipidomics Flux Analysis
Shakti Gupta,† Mano Ram Maurya,† Daren L. Stephens,‡ Edward A. Dennis,‡ and Shankar Subramaniam†‡§*
†Department of Bioengineering, and ‡Departments of Chemistry and Biochemistry and Pharmacology, School of Medicine, University of
California, San Diego, La Jolla, California; and §Graduate Program in Bioinformatics, University of California, San Diego, La Jolla California
ABSTRACT There is increasing evidence for a major and critical involvement of lipids in signal transduction and cellular
trafﬁcking, and this has motivated large-scale studies on lipid pathways. The Lipid Metabolites and Pathways Strategy consor-
tium is actively investigating lipid metabolism in mammalian cells and has made available time-course data on various lipids in
response to treatment with KDO2-lipid A (a lipopolysaccharide analog) of macrophage RAW 264.7 cells. The lipids known as
eicosanoids play an important role in inﬂammation. We have reconstructed an integrated network of eicosanoid metabolism
and signaling based on the KEGG pathway database and the literature and have developed a kinetic model. A matrix-based
approach was used to estimate the rate constants from experimental data and these were further reﬁned using generalized
constrained nonlinear optimization. The resulting model ﬁts the experimental data well for all species, and simulated enzyme
activities were similar to their literature values. The quantitative model for eicosanoid metabolism that we have developed
can be used to design experimental studies utilizing genetic and pharmacological perturbations to probe ﬂuxes in lipid
pathways.INTRODUCTION
Lipids are the main structural components of cellular
membranes and facilitate compartmentalization of the cell
in different organelles, e.g., mitochondria, nucleus, etc., for
the efficient functioning of various processes. Traditionally,
lipids are only associated with cellular roles involving energy
storage and used as structural building blocks for compart-
ments. Recent developments in lipid research have identified
the important role of lipids in modulating cellular trafficking
and cellular signaling. There is increasing recognition that to
understand cellular processes, our current knowledge of
genomics and proteomics has to be complemented with
knowledge of lipids and other metabolites. Lipids have been
classified into six major categories (fatty acyls, glycerolipids,
glycerophospholipids, sphingolipids, sterol lipids, and pre-
nols) (1). Each category of lipids exhibits distinct roles in
various cellular processes and disease in addition to cross
talk. For example, fatty acyls contribute to inflammation,
rheumatoid arthritis, sepsis, and asthma; sphingolipids regu-
late cell proliferation, apoptosis, and cell differentiation;
and sterols play a central role in atherosclerosis (2). Thus,
the quantification and modeling of lipid synthesis and
metabolism opens new opportunities for systems-level anal-
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In this article, we have focused on a class of fatty acyls,
namely, the eicosanoids. For a recent review of all of the ei-
cosanoid biosynthetic and degradative pathways, see
Buczynski et al. (3). Eicosanoids are derived from AA, a
20-carbon fatty acid, and are divided into four subclasses:
prostaglandins, thromboxanes, leukotrienes, and other
oxidized products. Prostaglandins have been found to
mediate pain, fever, and other symptoms associated with
inflammation, and have been studied extensively (4,5).
Prostaglandin G/H synthase (EC 1.14.99.1; COX) catalyzes
the synthesis of prostaglandins from AA and has been
targeted for treating inflammation, musculoskeletal pain,
and other conditions (6). Even simple pharmaceutical
agents including aspirin and ibuprofen, COX inhibitors,
are used extensively in daily life (4). Recently, a new gener-
ation of COX-2 inhibitors, including celecoxib (Celebrex)
and rofecoxib (Vioxx), were used for the treatment of oste-
oarthritis and acute pain conditions, but most of these have
exhibited severe side effects, as evidenced from the recall
of Vioxx (7). Insufficient accounting for the important
interactions between different proteins and metabolites in
drug discovery is one plausible explanation for such side
effects. This suggests an increasingly important role of
quantitative and predictive modeling in drug-discovery
research.
There are only a few models of AA metabolism available
in the literature (8). Furthermore, due to the lack of avail-
ability of large-scale data, the quantification of intermediate
metabolites and interactions are not reliable in these
models. The Lipid Metabolites and Pathways Strategy
(LIPID MAPS) consortium (9) has quantified the global
doi: 10.1016/j.bpj.2009.03.011
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oped mass spectrometry-based methods to quantitatively
measure the changes in lipid metabolites in RAW 264.7
macrophage cells. Time-course data in response to the
treatment of macrophages with KDO2-lipid A (an LPS
analog) has been collected. This data is reported herein,
and additional data is freely available online (9). The
goal of the work presented here is to construct a predictive
kinetic model for eicosanoid metabolism and signaling
using the lipid pathways derived from the KEGG pathway
database and literature, and the time-course data from
LIPID MAPS. This manuscript is organized as follows.
In the next section, we briefly discuss the experimental
data preprocessing and present the methodology used to
estimate the rate parameters. In the subsequent section,
we present the results of parameters estimation and
validation of the model, followed by a discussion and
conclusion.MATERIALS AND METHODS
Network simpliﬁcation
We have developed a detailed metabolic and signaling reaction network
comprising the production and consumption of AA using the information
available in the literature (10–17) and the KEGG pathways database (18)
(Fig. 1 a). VANTED software was used to draw these networks (19). The
detailed network contained many unmeasured metabolites. One of the
steps in our matrix-based fast algorithm for parameter estimation required
experimental data on all metabolites except the leaf nodes/metabolites in
the network. The leaf nodes (last metabolite in each branch of the
network) were exempted, because the reactions leading to the unmeasured
leaf metabolites were combined with the default degradation of their
precursors. The network was simplified to include only the measured
metabolites by using two simple rules that are commonly used in chem-
ical reaction kinetics, metabolic engineering, and systems biology (20).
First, multistep reactions with unmeasured intermediate metabolites were
lumped into a single step containing measured metabolites. For example,
in the reaction A/ B/ C, if A and C are measured, and B is unmea-
sured, then the reaction has been simplified to A/ C. When metabolites
were involved in unmeasured branches of pathway or leaf-nodeFIGURE 1 Detailed network (a) and
simplified network (b) for LPS/
KDO2-lipid A stimulated eicosanoid
metabolism and signaling pathway.The
numbers above the arrows are reaction
numbers (Table 1), and default degrada-
tion reactions are not labeled. Black
lines represent lipid metabolism and
gray (red in online version) indicate
signaling pathways. Metabolites and
enzymes are represented in rectangular
boxes and ovals boxes, respectively.
The measured and unmeasured metabo-
lites are differentiated by thick and thin
borders, respectively. For full names of
metabolites, refer to the abbreviations
list. Signaling/transporter proteins:
FAT, fatty acid transporter; ERK, extra-
cellular receptor kinase; cPLA2, cyto-
plasmic phospholipase A2; PKC,
protein kinase C; NF-kB, nuclear factor
kappa beta.
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degradation reactions. Second, the enzymes, which were not regulated by
other proteins or metabolites, were eliminated from the reaction, with the
assumption that their activities remain constant during such processes.
When an enzyme is regulated, it is preserved in the simplified pathway
along with its signaling connections. Fig. 1 b represents the simplified
network map containing the essential components of lipid metabolism
and signaling. In this network, PGH2, an unmeasured metabolite, has
been retained because of its role as an intermediate in the generation of
more than one metabolite. More discussion on treatment of PGH2 in
the model is presented in the section on Kinetic modeling and parameter
estimation.
Experimental data and preprocessing
The LIPID MAPS consortium has developed a mass spectrometry-based
method for measuring all the major lipids in mammalian cells after treatment
with KDO2-lipid A. RAW 264.7 cells, grown in 10% serum, were used in
the experiments. All metabolites were measured in pmol/mg-DNA units.
To understand lipid metabolism under the normal and disease state, the
experiments were performed and time-courses of lipids were measured
under two conditions: (a) normal condition designated as control and (b)
inflamed condition (stimulated by KDO2-lipid A). LPS activates the cyclo-
oxygenase (COX) enzyme and inhibits the lipoxygenases (21). Thus, COX
products (prostaglandins) were detected in the experiments and lipoxyge-
nase products (leukotrienes) were undetectable. Time series comprised of
eight points, at 0, 0.5, 1, 2, 4, 8, 12, and 24 h, were measured with three bio-
logical replicates consisting of three technical replicates each. The three
technical replicate experiments were performed on the same day with a single
batch of cells. In addition, each time course was repeated three times
on different days with different batches of cells (biological replicates).
For kinetic modeling purposes, outlier points were detected by a simple
t-test and were excluded at each time point. The resulting data from
all the replicates were averaged at each time point. Data were processed
for all metabolites under treatment with KDO2-lipid A and control
conditions.
Kinetic model and parameter estimation
We have developed a kinetic model of the simplified lipid network. The
reaction rates were described by linear or law-of-mass-action kinetics,
with the assumption that for enzymatic reactions, the substrate concentra-
tions are much smaller as compared to the correspondingMichaelis constant,
Km. For example, the following types of reaction schemes and rate expres-
sions were used:
This is similar to a scheme used in the modeling of calcium dynamics in our
laboratory (22). Because of the scarcity of information on transcriptional,
translational and posttranslational regulation of various enzymes, and also
for simplification, enzyme regulation was modeled by formulating the
rate parameter for the enzyme as a linear function of its regulatory mole-
cules. For example, COX has two isoforms, COX-1 and COX-2. COX-1
is constitutive and COX-2 is an inducible enzyme. The activity of COX-2
is modified by DG and LPS. This effect was functionally captured through
the reactions
Reaction Rate expressions
A/ B k*[A]
A þ B/ AB k*[A]*[B]
[Enz] A/ B k*[Enz]*[A]
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and LPS (k10*[DG] þ k11*[LPS] þ k12). The flux expressions obtained
from this scheme were linear in rate parameters and nonlinear in metabolite
concentrations. The matrix-based approach to estimate the rate constants
is described below in terms of the reaction numbers labeled in Fig. 1 b
and listed in Table 1. This approach is an extension of a previous approach
used for rate-parameter estimation for metabolic reactions using steady-
state data (23). Equation 1 describes the rate of change of [PGH2] and
[PGD2].
d½PGH2
dt
¼ k10½DG½AA þ k11½LPS½AA þ k12½AA
k13½PGH2  k15½PGH2  k17½PGH2
d½PGD2
dt
¼ k17½PGH2  k18½PGD2  k19½PGD2
;
(1)
where the rate constants, ki (i¼ 10, 11, 12, 13, 15, 17, 18, 19), are as defined
in Table 1.
TABLE 1 The estimated parameter values for eicosanoids
model
No. Reactions Parameter Names Values
1 [LPS] FA/ AA k1 355.637
2 FA/ AA k2 10
15
3 DG/ AA k3 10
15
4 AA/ k4 10
15
5 [DG] GPCho/ AA k5 10
15
6 [LPS] GPCho/ AA k6 0.330
7 GPCho/ AA k7 10
15
8 AA/ HETE k8 0.007
9 HETE/ k9 0.187
10 [DG] AA/ PGH2 k10 0.024
11 [LPS] AA/ PGH2 k11 0.111
12 AA/ PGH2 k12 0.098
13 PGH2/ PGE2 k13 0.204
14 PGE2/ k14 10
15
15 PGH2/ PGF2a k15 0.061
16 PGF2a/ k16 10
15
17 PGH2/ PGD2 k17 3.116
18 PGD2/ PGJ2 k18 0.054
19 PGD2/ dPGD2 k19 0.029
20 dPGD2/ k20 0.014
21 PGJ2/ dPGJ2 k21 0.034
22 dPGJ2/ k22 0.116
‘‘[DG]’’ and ‘‘[LPS]’’ indicate the effects of signaling (molecules) in
the reaction. X / represents the default degradation of metabolite X.
The unit of first-order reaction is 1/h. The unit of second-order reaction
is 1/h when it involves either FA or LPS as one of the metabolites, as
we have used scaled profiles for these variables. The unit of second-order
reaction is mg DNA/(ratio int * h) when it involves DG as one of the
metabolites.
½DGAA/k10 PGH2
½LPSAA/k11 PGH2
AA/
k12
PGH2
for inducible activity of COX-2 because of DG
for inducible activity of COX-2 because of LPS
for constitutive activity of COX-1 and COX-2
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unknown, then the ODEs can be rearranged in a matrix format as shown
in Eq. 2.
(1015). The algorithm of fmincon does not require a matrix form. Thus,
numerical integration was used (e.g., MATLAB function ode23) to simulate
the system to circumvent the discretization problems. The combined use of
" d½PGH2
dt
d½PGD2
dt
#
¼
 ½AA ½DG½AA ½LPS½AA  ½PGH2  ½PGH2  ½PGH2 0 0
0 0 0 0 0 ½PGH2  ½PGD2  ½PGD2

2
66666666664
k10
k11
k12
k13
k15
k17
k18
k19
3
77777777775
Y ¼ X  b
: (2)The coefficients in the matrix X are linear/nonlinear functions of metabolite
concentrations. All the equations used in the simulation are listed in an
Appendix. Experimental data were available for all metabolites except
PGH2 in the simplified network. To be able to use this matrix-based
approach, a time-course profile was assumed for the PGH2 for this step.
The shape for PGH2 was assumed based on the average shape of AA and
PGD2, with a maximum concentration of 25 pmol/mg DNA. A low concen-
tration was assumed based upon its unstable nature and the value reported in
the literature (24). With the assumed PGH2 profile, X is completely defined.
The lefthand side of the equations (matrix Y) was computed using discreti-
zation and the experimental data (Eq. 3).
dx
dt

t¼ tk
¼ xjt¼ tkxjt¼ tk1
tk  tk1 : (3)
To compute the unknown parameter vector (b), matrix X was required to
contain only known entries, justifying the retention of only measured metab-
olites in the simplified network.
Equation 2 contains known matrices X and Y, and the only unknown in
this equation is the rate-constant vector, b, which can be computed as
b ¼ ðXTXÞ1ðXTYÞ(the least-squares solution, which is the fastest
method). However, XTX can be singular in many practical applications.
Another problem is that the estimated values in matrix b may contain nega-
tive values, which are not viable for biological systems. The problem of
singularity can be eliminated using principal-component regression (PCR)
(25), but PCR does not prevent the negative solutions. Hence, we used
the constrained least-squares approach (MATLAB (The MathWorks, Natick
MA) function lsqlin), which optimized the solution with objective function
(Eq. 4), with additional constraints that all parameter values have to be
positive.
minkYXbk2 whereY andXb are : dy
dt

exp
and
dy
dt

pred
:
(4)
The above method minimized the fit error (Eq. 4) between the experimental
slope (d/dt computed using experimental data) and the predicted slope (d/dt
computed using predictions) instead of between the experimental and pre-
dicted data. Hence, the resulting parameters did not fit the experimental
data well. However, they serve as good initial values for the parameter esti-
mation. The estimated values of the parameters were further refined by using
generalized constrained nonlinear optimization (MATLAB function fmin-
con), where the objective (Eq. 5) was to minimize the weighted fit error
between the experimental and predicted metabolite concentrations and their
slopes (time derivative), except in the case of PGH2. The maximum concen-
tration of PGH2 was optimized at ~25 pmol/mg DNA to maintain its low
concentration in the simulation (24). The positivity of parameters was
imposed by constraining the lower limit of parameters to a small numberlsqlin and fmincon made the overall process computationally efficient. The
objective function for use with fmincon was
min
K;X0
0
BBB@
w1
Pnsp
i¼ 1
 Pnt
j¼ 1

yi;j;exp  yi;j;predðK;X0Þ
2!þ
w2
Pnsp
i¼ 1
 Pnt
j¼ 1

dy
dt

i;j;exp
dy
dt

i;j;pred
ðK;X0Þ
2!
1
CCCA;
K : parameters ðrate constantsÞ
X0 : Initial conditions ðspecies concentrationsÞ
(5)
where nt is the number of time points and nsp is the number of species. The
first term represents the fit error between the experimental and predicted
concentrations, and the second term represents the fit error between their
experimental and predicted derivatives. Different weights (wi) can be as-
signed to these two terms to improve the fit. For this study, w1 and w2 are
set to 1 and 0, respectively.
The initial concentrations of the metabolites were also optimized in
a narrow range around the experimental values. When data were available
for more than one condition, all the data were used to compute the fit error
by simulating the model several times individually and minimizing the
objective function collectively. We also observed that when arbitrary initial
guesses were used, fmincon was either diverging or converging to erroneous
solutions. Thus, the matrix approach (lsqlin) was very useful for providing
an initial guess for the parameter-estimation.
RESULTS
Good ﬁt to experimental data
ODEs were generated for all metabolites in the network, and
effective rate constants were estimated for the simplified
eicosanoid reaction network using the approach described in
Materials and Methods. The simplified model is a reliable
predictivemodel, as evidenced by the good fit to experimental
data. Table 1 lists the reactions and the corresponding esti-
mated reaction-rate parameters included in the model. The
large variation in experimental ‘‘control’’ data, especially
for glycerolipids, glycerophospholipids, and sphingolipids
(9), indicated the non-steady-state condition in control exper-
iments. The assumption of steady state was circumvented by
including (fitting) data obtained in two experimental scenarios
during parameter estimation, one in which cells were treated
with KDO2-lipid A and a corresponding control data set.Biophysical Journal 96(11) 4542–4551
4546 Gupta et al.The wide range of metabolite concentrations also created
a problem in optimization of the parameters. The maximum
concentration of metabolites varied between 8 pmol/mg
DNA (for HETE) and 400 pmol/mg DNA (for AA). Due to
the two orders of magnitude difference in metabolite concen-
trations, the metabolites with higher concentrations contrib-
uted more to the objective function (fit error) (Eq. 5) than
did those with lower concentration. This resulted in a rela-
tively poor fit for the metabolites with lower concentrations.
To resolve this issue, the errors between experimental values
and predicted values for each metabolite were calculated and
scaled/normalized by its maximum experimental value.
Then, the sum of squares of the normalized fit error on all
metabolites was minimized. This scaling essentially normal-
ized the maximum experimental concentrations to 1 for all
metabolites and resulted in approximately equal weight for
all metabolites. It should be noted that integration was still
performed in absolute concentration values for all metabo-
lites. Further, the data were measured at irregular time inter-
vals (longer intervals at later times). This led to relatively
poor fit at later time points. To resolve this issue, the point-
wise error was scaled by the square root of the length of the
time interval.
Fig. 2 shows the simulation results (27). For most time
points, the difference between the predicted and experi-
mental data was within the standard error of the mean
(Fig. 2). The good fit was obtained for all metabolites under
both conditions (treatment and control). The only difference
between the treatment and control scenarios was the presenceBiophysical Journal 96(11) 4542–4551and absence of KDO2-lipid A. To capture this scenario in the
simulation, nonzero and zero KDO2-lipid A profiles were
used for the treatment and control sets, respectively. Good
fit to control data is also significant from both the biological
function and the mathematical analysis point of view. The
control scenario provided a condition similar to steady state
at time 0 h and constrained the optimized solution such that
the fit to treatment data captures only the effect of treatment.
Thus, good fit to both the datasets suggested that the
topology of the simplified network was correct and captured
the important metabolic and signaling effects.
We assumed constant fatty acid concentration ([FA] ¼1)
in the media. The assumption of a constant fatty acid profile
is reasonable, since the total amount of eicosanoids is much
smaller compared to the total amount of fatty acid in the
media. Thus, the production of eicosanoids should not affect
the concentration of fatty acid in the media. Its uptake was
constitutive and also induced by LPS. The timescale of
KDO2-lipid A signaling for the activation of eicosanoid path-
ways and fatty acid transport is largely unknown, as the
dynamics of the activation of Toll-like receptor 4 is complex.
We have manually optimized the time course of LPS to get
a good fit. Upon treatment, the effective level of KDO2-lipid
A (or the activity of Toll-like receptor 4) increased from 0 to
1 during the first half-hour and then decreased back to 0 in the
next 1.5 h. The rate constant k1 is large compared to other rate
constants (Table 1). This is because we have used scaled and
dimensionless values for LPS and FA, in contrast to our use
of pmol/mg DNA for other metabolites.FIGURE 2 Simulation of kinetic
modeling of the simplified lipid
network: fit of the predicted response
(control and treatment with KDO2-lipid
A) to the corresponding experimental
data for RAW 264.7 cells. Ctrl, control
set; Trt, KDO2-lipid A treatment set.
The error bars shown for the experi-
mental data represent the standard error
of mean.
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Wehave also validated ourmodel by excluding fromobjective
function minimization the data on one of the intermediate
metabolites. The rate parameters were estimated, and the
predictions were compared with the experimental data. The
values of the parameters thus obtained were approximately
similar to the values in the previous simulation/optimization
(listed in Table 1), except for the AA degradation constant.
In the previous simulation, the profile of PGH2 was unknown
and its maximum concentration was optimized and con-
strained at ~25 pmol/mg DNA, but during the validation, we
used this profile of PGH2 in the optimization. There are two
intermediate metabolites present in the network: PGD2 and
PGJ2. The validation was performed on both of these metabo-
lites, and satisfactory results were obtained. The results of vali-
dation by excluding PGD2 (the fitted response for other
metabolites during optimization and the predicted response
of PGD2 using the resulting parameter values) are shown in
Fig. 3. Simulation results are not shown for validation by
exclusion of PGJ2. There is a slight deterioration in the quan-
titative fit, but the qualitative shape of the predicted time
course is in good agreementwith the experimental time course.
Parametric sensitivity and timescale analysis
Parametric sensitivity
Parametric sensitivity analysis was performed by varying
each parameter (one at a time) by twofold up and downfrom its original (optimized) value. The sensitivity of each
metabolite was studied by plotting the fold change in its
maximum concentration, as compared to the maximum
concentration corresponding to the original value of the
parameter, versus the ratio change in the value of the per-
turbed parameter (Fig. 4). The numerical values of the sensi-
tivity, i.e., the slope of the plot at the optimized value of the
parameter, are listed in Table S1 of the Supporting Material.
For each parameter and each metabolite, monotonic increase,
decrease, or no change was observed, depending upon the
respective locations of the parameter and the metabolite
chosen in the network. The change in the parameters
belonging to the upper part of the network produced a larger
change in almost all metabolites as compared to the change
in the parameters belonging to the lower part of the network.
For example, the change in parameter k1 ([LPS] FA/ AA)
(Fig. S1) produced an increase in all metabolites (sensitivity
~ 0.8); the change in k17 (PGH2/ PGD2) produced changes
in all metabolites downstream of PGH2. Although PGH2,
PGE2, and PGF2a decreased (sensitivity ~ 0.9), PGD2,
PGJ2, dPGD2, and dPGJ2 increased (sensitivity ~ 0.1), but
no significant change was observed for AA and HETE
(Fig. 4 and Table S1). Sensitivities are consistent with the
structure of the biochemical reaction network (Fig. 1 b). A
change in k17 has a direct impact on the peak height of
PGH2. Because PGE2 and PGF2a are immediately down-
stream of PGH2, they are affected to the same degree as
PGH2 (Fig. 4). In comparison, the peak height of PGD2 is
affected to a much lesser degree, because the influx toFIGURE 3 Validation of the eicosa-
noid network with leave-one-out inter-
mediate metabolite: PGD2 was omitted
from the objective function used in opti-
mization. The solution obtained using
this method fits the experimental data
for PGD2 reasonably well. The error
bars shown for the experimental data
are standard-error of mean.Biophysical Journal 96(11) 4542–4551
4548 Gupta et al.FIGURE 4 Result of parametric
sensitivity analysis for parameter k17
(PGH2/ PGD2). The x axis indicates
the ratio of the perturbed to the original
(optimized) value of the parameter, and
the y axis indicates the fold change in
the maximum value of state variables
(metabolites).PGD2 is k17*[PGH2]. When k17 increases, [PGH2] decreases,
so the net effect on k17*[PGH2] is much smaller. PGJ2,
dPGD2 and dPGJ2 are downstream of PGD2 and are affected
to the same degree as PGD2. Small to moderate sensitivities
(Table S1) suggest that the biochemical system is robust with
respect to parametric perturbations.
Timescale
Timescale characterization is important in understanding the
metabolite dynamics and its response time. The analysis was
performed by computing eigenvalues and eigenvectors of the
Jacobian matrix of ordinary differential equations at steady-
state conditions. The steady-state was identified by simu-
lating the system corresponding to the control condition
(no stimulus) for a long time (t ¼1000 h). The Jacobian
was computed through numerical differentiation of the
expressions on the righthand sides of the ODEs with respect
to the state variables. The eigenvalues are split into three
broad ranges. For each eigenvalue, the metabolites with
substantial contribution to the corresponding eigenvector
were identified. Depending upon the eigenvalues and metab-
olites significantly contributing to the corresponding eigen-
vectors, these metabolites have been divided into the three
categories listed in Table 2. When a metabolite contributed
significantly in two or more eigenvectors spanning two
different eigenvalue ranges, it was assigned to the smaller
eigenvalue range, because the fast time manifold only deter-
mines its initial transients and the slow manifold governs the
later response leading to steady state. Similar results could beBiophysical Journal 96(11) 4542–4551gleaned by inspecting the time course of the metabolites,
but the eigenvalue-decomposition-based characterization is
more rigorous and contributes to a better understanding of
the temporal evolution in a systemic context. Medium-time-
scale metabolites go up and return to basal levels within 24 h;
however, slow-timescale metabolites show monotonic
increases up to 24 h (Fig. 2). As discussed in the Results
section, PGH2 is unstable and maintains its low concentra-
tion inside the cell. Thus, its fast timescale is a resultant of
its low concentration, its involvement in a high rate of
production from AA, and its fast conversion into PGD2.
DISCUSSION
The metabolism of AA in macrophages has been the subject
of long-standing investigations because of its involvement in
inflammation and the immune system response. Earlier
experiments focused on a specific metabolite or enzyme in
the network. LIPID MAPS performed experiments to
TABLE 2 Results of eigenvalue based timescale analysis of
metabolites
Fast (~1 h) Medium (~10 h) Slow (~50 h)
PGH2 AA PGE2
PGD2 PGF2a
HETE PGJ2
dPGD2
dPGJ2
Modeling of Eicosanoid Pathway 4549measure a large number of metabolites, proteins, and genes
using high-throughput techniques under identical conditions.
This data is valuable for studying interactions between
different lipid metabolites, proteins, and genes. To validate
the LIPID MAPS data, we have compared the LPS-induced
time-course profile with those in the existing literature for
various metabolites. The time courses for AA, PGD2,
PGE2, PGF2a, and dPGD2 were collected from the literature
(28–32) and found to be qualitatively similar to the LIPID
MAPS data and model simulations.
Multiple sources of AA and lumped nature
of the rate parameters for the upstream part
of the network
Lipid metabolism and signaling are complex processes and
the mechanisms involved are only partially known. The
quantitative contribution of various potential sources of
AA production is not clearly known. Theoretically, AA
can be produced from glycerophospholipids such as GPCho
or glycerolipids such as DG and can also get transported
from/to the extracellular media, perhaps through CoASH
pools. We have accounted for all three sources of the AA
production. The timescales/response times of the three sour-
ces are largely unknown, and hence, we cannot distinguish
among them. Further, no information is available about
fluxes of conversion of AA into PGH2, acyl coenzyme A,
and HETE (Fig. 1 b). Consequently, we have manually opti-
mized the profile of LPS to get the best fit. Thus, we have less
confidence in the quantitative values of parameters for AA
production from the three sources than for those of parame-
ters for conversion of AA into prostaglandins. This is why
we chose COX, PGDS, and PGES activities to compare
against their literature values instead of the enzymes
involved in AA production. If experimental data related to
acylation of AA becomes available in the future, its utiliza-
tion will result in the readjustment of unknown parameters
related to the production of AA and its acylation. The param-
eters of prostaglandin pathways will not be affected signifi-
cantly. Hence, this model is reliable.
Rate parameters for the enzymes
We compared the effective rate constant for the enzymes
COX, PGDS (EC 5.3.99.2), and PGES (EC 5.3.99.3) with
the corresponding values reported in the literature (33–36).
Since the concentrations in LIPID MAPS experimental
data and literature values were reported in units of pmol/mg
DNA and mmol/min/mg of enzyme-enriched protein, respec-
tively, we used appropriate conversion factors, assuming the
cell diameter to be 10 mm and other relevant information
about the average cell density, percentage protein content,
and total percentages of RNA and mRNA per cell. For the
amount of COX protein per cell, we used COX mRNA/total
RNA data from Chan et al. (37) and assumed that this ratio is
the same at the protein level. The values reported in the liter-ature were based on in vitro measurements with partially
purified protein. Thus, we assumed that the literature values
represented basal activity and compared these activities (flux
through the enzyme) with predicted activities of these
enzymes in the ‘‘control’’ simulation. Our computed value
for COX (1013 mmol/min/cell) is within one order of magni-
tude of the reported value (1014 mmol/min/cell) (37). This
discrepancy in the COX parameter value can be attributed
to many factors, e.g., experimental conditions, modeling
approximations, differences between the cell types used in
these experiments, etc. For PGDS and PGES, we used
reverse transcriptase PCR data from references (38,39) to
compare with the COX amount and calculated its activities.
A comparison between the simulated and experimental
values for all three enzymes is shown in Table 3.
CONCLUSIONS
Systems biology approaches have contributed to our under-
standing of the gene, protein, and metabolic networks and
are proving to be beneficial for pathway-based drug
discovery. In this study, we used a supervised approach
to integrate legacy information on the lipid pathways with
novel experimental data to develop a simple kinetic model
of the eicosanoid metabolic pathway. Signaling and meta-
bolic pathways were reconstructed from KEGG and the ex-
isting literature. Based upon the network map reconstructed,
we developed an ODE-based mathematical model. A two-
step approach was used for parameter estimation. In the first
step, a matrix-based approach provided an initial guess. The
parameter values were further refined in the second step.
This approach makes the overall process computationally
efficient. It can be noted that to utilize the matrix-based
fast approach, nonsaturation linear kinetics were used. To
estimate the parameters more accurately, Michaelis-Menten
kinetics can be used for enzymatic reactions. The resulting
model fit the experimental data well for all species and
demonstrated that the integrated metabolic and signaling
network and the experimental data are consistent with
each other. The robustness of the network structure and
model parameters was also validated through leave-one-
out type experiments and parametric sensitivity analysis.
The fluxes through COX, PGDS, and PGES, obtained
from the simulation, were consistent with their literature
values.
TABLE 3 Comparison of computed enzyme activities with the
corresponding literature values
Enzyme EC No.
Literature
values (mmol/
min/mg protein)
Literature
values (mmol/
min/cell)
Computed/
optimized values
in our model
(mmol/min/cell)
COX 1.14.99.1 3.96 1014 1013
PGDS 5.3.99.2 1.7 1014 1014
PGES 5.3.99.3 2 1015 1015Biophysical Journal 96(11) 4542–4551
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The flux expressions for the reactions shown in Fig. 1 b are
v1 ¼ k1[PIP2][LPS] v2 ¼ k2[PIP2] v3 ¼ k3[DG]
v4 ¼ k4[AA] v5 ¼ k5[GPCho][DG] v6 ¼ k6[GPCho][LPS]
v7 ¼ k7[GPCho] v8 ¼ k8[AA] v9 ¼ k9[HETE]
v10 ¼ k10[AA][DG] v11 ¼ k11[AA][LPS] v12 ¼ k12[AA]
v13 ¼ k13[PGH2] v14 ¼ k14[PGE2] v15 ¼ k15[PGH2]
v16 ¼ k16[PGF2a] v17 ¼ k17[PGH2] v18 ¼ k18[PGD2]
v19 ¼ k19[PGD2] v20 ¼ k20[dPGD2] v21 ¼ k21[PGJ2]
v22 ¼ k22[dPGJ2].
The differential equations describing the rate of change of metabolite
concentrations are
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